A cohort study of 338 patients with NSCLC has demonstrated that intestinal Akkermansia muciniphila is significantly accompanied by clinical benefits with increased response rates and OS following PD-1 blockade [122]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.